The Future of Healthcare Innovation: Amgen Takes Center Stage at Citi's 2025 Global Healthcare Conference
In a move that’s sure to spark excitement in the biotech and healthcare sectors, Amgen (NASDAQ:AMGN) is set to present at Citi's 2025 Global Healthcare Conference on December 3, 2025, at 1:45 p.m. ET. But here’s where it gets even more intriguing: leading the charge will be two of Amgen’s top executives—Peter Griffith, Executive Vice President and Chief Financial Officer, and Jay Bradner, Executive Vice President of Research and Development. Their insights are expected to shed light on Amgen’s groundbreaking work in tackling some of the world’s most challenging diseases. And this is the part most people miss: the webcast will be available not just to investors, but also to the general public, offering a rare glimpse into the company’s vision for the future of healthcare.
The presentation, part of a series of selected updates on Amgen’s business developments, will be accessible on the company’s website under the Investors section. But here’s the controversial part: as Amgen continues to push the boundaries of biotechnology, questions arise about the ethical implications of using human genetic data in drug development. Is this innovation at its finest, or are we crossing lines we shouldn’t? We’d love to hear your thoughts in the comments.
For over 40 years, Amgen has been a pioneer in the biotechnology industry, leveraging cutting-edge technology and human genetic data to develop innovative medicines. From cancer and heart disease to osteoporosis, inflammatory diseases, and rare conditions, Amgen’s pipeline is both broad and deep, building on its existing portfolio of life-changing treatments. In 2024, the company was recognized as one of the 'World's Most Innovative Companies' by Fast Company and one of 'America's Best Large Employers' by Forbes, among other accolades. Amgen is also a key player in major financial indices, including the Dow Jones Industrial Average® and the Nasdaq-100 Index®.
To stay updated on Amgen’s latest advancements, visit their website at Amgen.com or follow them on social media platforms like X (formerly Twitter), LinkedIn, Instagram, YouTube, and Threads. For media inquiries, contact Elissa Snook at 609-251-1407, and for investor relations, reach out to Casey Capparelli at 805-447-1746.
Thought-provoking question for our readers: As Amgen continues to lead in biotech innovation, how do we balance the promise of genetic-based therapies with potential ethical concerns? Share your perspective below!
